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Abstract 
The 1)ț% VLJQDOLQJ pathway is implicated in breast cancer and bone metastasis. However, the 
bone-DXWRQRPRXVFRQWULEXWLRQRI1)ț% to breast cancer-induced osteolysis is poorly understood. 
Here, we report that pretreatment of osteoblasts with the sesquiterpene lactone Parthenolide (PTN), 
DYHULILHG1)ț%LQKLELWRUSULRUWRH[SRVXUHWRconditioned medium from human and mouse breast 
cancer cell lines enhanced osteoblast differentiation and reduced osteoblast ability to stimulate 
osteoclastogenesis. PTN prevented breast cancer-induced osteoclast formation and reduced the 
ability of breast cancer cells to prolong osteoclast survival and to inhibit osteoclast apoptosis. In 
vivo, administration of PTN in immuno-competent mice reduced osteolytic bone loss and skeletal 
tumour growth following injection of the syngeneic 4T1-BT1 cells and reduced local osteolysis 
caused by conditioned medium from human and mouse osteotropic breast cancer cell lines. 
Mechanistic studies revealed that 1)ț% inhibition by PTN in osteoblasts and osteoclasts was 
accompanied by a significant increase in E-catenin activation and expression. Collectively, these 
UHVXOWVUDLVHWKHSRVVLELOLW\WKDWFRPELQHGWDUJHWLQJRI1)ț%DQGȕ-catenin signalling in the tumour 
microenvironment may be of value in the treatment of breast cancer related osteolysis.  
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1. Introduction 
Skeletal related events are a common cause of morbidity in patients diagnosed with secondary 
breast cancer in bone [1-3]. Bone metastases related to advanced breast cancer are osteolytic, and 
are caused by stimulation of osteoclast formation and bone resorption by breast cancer cells and/or 
their derived factors in the skeleton [3, 4]. A number of breast cancer- and bone-derived factors 
including receptor activator of nuclear factor kappa-B (RANK) ligand RANKL, tumour necrosis 
factor alpha (TNFD), interleukin 1 beta (IL1E  and Cluster of differentiation 40 ligand (CD40L) 
influence breast cancer - bone cell interactions[5-8]. Binding of these ligands to their respective 
receptors activates the canonical NFț%VLJQDOOLQJ pathway by initiating the recruitment of receptor-
associated factors (TRAF) TRAF2 and TRAF6[6-8]. This in turn leads to the binding of ,ț%NLQDVH
(IKK) alpha (IKKD) and beta (I E) the regulatory subunit J[9, 10]. Once activated, 
the IKKDEJ complex phosphorylates and triggers the proteasomal degradation of INB that results 
in NFNB nuclear translocation[6].  
A number of studies have reported that mice deficient in NFNB1/2, TRAF2, TRAF6, IKKD or 
IKKE exhibited high bone mass due to osteoclast inhibition[11-15]. Furthermore, pharmacological 
inhibition of NFNB activation reduced osteoclast number and protected against bone loss in models 
of inflammation and oestrogen deficiency[16-20]. NFNB activation is also involved in the 
regulation of osteoblast differentiation and bone formation. For example, FD  
WUDQVIRUPLQJJURZWKIDFWRUEHWD7*)ȕ induces osteoblast apoptosis[1, 3, 21] and knockdown of 
IKK in osteoblasts and their precursors enhances bone nodule formation in vitro and stimulates 
bone formation in mice [22].  
There is also evidence to suggest that NFNB regulates osteoclast and osteoblast activity through its 
crosstalk with the Wnt/ȕ-catenin pathway[23]. In osteoblasts, activation of ȕ-catenin stimulates 
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bone formation and enhances the expression of runt related transcription factor 2 (Runx2), a key 
osteogenic factor essential for osteoblast differentiation [24-27]. $FWLYDWLRQ RI ȕ-catenin inhibits 
osteoclast formation [28-30] and activation of NFN%E\5$1./LQRVWHRFODVWV OHDGVWRȕ-catenin 
inhibition [31, 32]. Altogether, these findings implicate the NFNB/ȕ-catenin axis in the regulation of 
osteoclast and osteoblast activity and bone remodelling. 
2YHUUHFHQW\HDUVWKHUHKDVEHHQLQFUHDVLQJLQWHUHVWLQWKHUROHRI1)ț%LQWKHUHJXODWLRQRIbreast 
cancer bone metastasis [33, 34]. 1)ț% LQ EUHDVW FDQFHU FHOOV HQKDQFHV RVWHRFODVW IRUPDWLRQ DQG
promotes bone metastasis. Recent work carried out in our laboratories has shown that 
pharmacologic inhibitors of 1)ț% reduced osteolysis in a model of breast cancer osteolytic 
metastasis [33, 34]. However, the role RI 1)ț% ± and its interaction with ȕ catenin - in the 
regulation of osteoblast and osteoclast changes associated with breast cancer-induced osteolysis has 
not been investigated. Using a pharmacological approach that utilizes data from experiments using 
bone cells, organ cultures and immuno-competent mice, we showed that the sesquiterpene lactone 
Parthenolide (PTN), a verified inhibitor of NFNB[34-37], enhanced ȕ-catenin expression and 
activity in osteoblasts and osteoclasts in vitro, and protected against breast cancer-induced 
osteolysis ex vivo and in vivo. 
2. Materials and methods 
2.1. Reagents and cells 
The sesquiterpene lactone PTN was purchased from Tocris Biosciences (Bristol, UK). Parental and 
osteotropic clones of human MDA-MB-231 and mouse 4T1-BT1 (representative of triple-negative), 
human MCF7 (hormone sensitive breast cancer cell lines), and the osteoblast-like cells Saos-2 and 
MC3T3, and the macrophage-like cell (pre-osteoclasts) RAW 264.7 were purchased from ATCC 
(Manassas, VA). The osteotropic sub clones of the triple negative human MDA-231-BT1 and BT2 
and mouse 4T1-BT1 and BT2 were generated by repeated passages in vivo and validated for their 
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ability to colonize bone and to cause osteolysis[38-40]. Tissue culture medium was obtained from 
Sigma-Aldrich (Dorset, UK). Primers for quantitative PCR were designed using the Roche website 
and obtained from Invitrogen (Paisley, UK) and probes were purchased from Roche Diagnostics 
Ltd. (East Sussex, UK). Antibodies were purchased from Cell Signalling Biotechnology (MA, 
USA) except rabbit anti-actin was obtained from Sigma-Aldrich (Dorset, UK). Mouse macrophage 
colony stimulating factor (M-CSF) was obtained from R&D Systems (Abingdon, UK) and RANK 
ligand (RANKL) was a gift from Patrick Mollat (Galapagos SASU, France)[16]. 
2.2. Animal experiments 
All experimental protocols were approved by the Ethics Committee at the Universities of 
Edinburgh and Sheffield and were conducted in accordance with the UK Home Office 
regulations.  
2.2.1. Intra-tibial injection in mice 
Balb/c female mice (10-week-old) received intra-tibial injection of mouse 4T1-BT1 breast cancer 
cells (4×103 cells) in the left leg and a sham injection of PBS into their right leg. On day 2, 
animals were divided into two groups (7 mice per group) and received intraperitoneal injection of 
either vehicle (Dimethyl sulfoxide (DMSO)/water, 1:10) or PTN (10mg/kg/day) for 12 days. 
Treatment regime used was chosen based on previous in vivo studies, which demonstrated that 
this agent has anti-resorptive and anti-metastatic effects[34]. Animals were euthanized 14 days 
post injection of 4T1-BT1 cells and bone architecture was assessed by micro±computed 
tomography (microCT, Brucker 1172 scanner, Brucker, Belgium)[41]. Skeletal tumor growth was 
measured on 2D microCT images using Image J (1.34s; NIH, Bethesda, MD, USA) and results 
were expressed as a percentage of total metaphyseal area. 
2.2.2. Supracalvarial injection in mice 
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C57BL/6 female mice (3-weeks-old) were divided into two groups (7 mice per group) and received 
intraperitoneal injection of either vehicle (DMSO/water, 1:10) or PTN (3mg/kg/day) for 6 days. On 
day 2, mice were injected subcutaneously over the calvarial bones (supra-calvarial) with 50PL of 
conditioned medium from human MDA-231-BT1, mouse 4T1-BT1 and human MCF7 breast cancer 
cells on 5 consecutive days[39]. Osteolytic bone loss in the calvarial bone was assessed using 
microCT at a resolution of 8Pm[41]. All mice injected with conditioned medium from human 
MDA-231 or MCF7 or mouse 4T1 did not exhibit any obvious physical signs of illness or 
inflammatory response. 
2.3. Micro-computed tomography 
Trabecular bone parameters were measured at the left proximal tibia (200 slices distal of the growth 
plate) using microCT analysis (Skyscan 1172 instrument (Brucker, Belgium) set at 60kV and 
150PA [41]. Images were reconstructed by the Skyscan NRecon program and analysed using 
Skyscan CTAn software (Brucker, Belgium) [41]. 
2.4. Bone histomorphometry 
Bone histomorphometry was performed on the proximal tibial metaphysis from mice as previously 
described [34, 42]. Briefly bones were fixed, sectioned using a Leica microtome (Solms, Germany) 
and tissue sections were stained with von Kossa, Paragon, tartrate-resistant acid phosphatase 
(TRAcP) and aniline blue. Static and dynamic bone histomorphometry were performed on 
trabecular bone (0.1 and 1mm distal to the growth plate) and three sections per samples were 
analysed using computer software based on the Aphelion Image Analysis tool kit (Adcis, 
He0rouville- Saint-Clair, France).  
2.5. Cancer cell ± mouse calvaria organ co-culture system 
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The effects of pharmacological inhibition of NFNB on local osteolysis induced by human and 
mouse cancer cell derived factors was studied ex vivo using an adaptation of the mouse calvarial 
organ culture as described in[42]. Briefly, neonatal mouse calvarias were isolated from 7-day-old 
mice, divided into equal halves along the medium sagittal suture and each half was placed into 
culture on stainless steel rafts in 48-well plates containing standard or conditioned medium. Tissue 
culture medium containing test agents was changed every 48 hours and the cultures were terminated 
after 7 days. Bone volume was assessed by using m CT at a resolution of 5Pm. 
2.6. Osteoblast cultures 
Primary osteoblasts were isolated from the calvarial bones of 2-day-old mice as previously 
described[43]. Primary calvarial osteoblasts or the osteoblast-like cells Saos-2 and MC3T3 were 
seeded into 12-well plates at 10 x 105 cells per well in standard alpha-MEM or DMEM respectively, 
supplemented with ȕ-JO\FHUROSKRVSKDWHȝ0DQG/-ascorbic acid (50 µg/ml) for up to 21 days. 
Osteoblast cell number, differentiation and bone nodule formation were determined by AlamarBlue 
assay, alkaline phosphatase (Alk Phos) assay and alizarin red (ALZ) staining as previously 
described[43].  
2.7. Osteoclast cultures 
Bone marrow (BM) cells were flushed from the long bones of 3-5 month old mice and primary 
osteoblasts were isolated from the calvarial bones of 2-day-old mice as previously described[43]. 
Osteoblasts were plated in 96-well plates (8 x 103 cells/well) for 24 hours and BM cells were added 
(2x105 cells/well). M-CSF-dependent osteoclast precursor cells generated as previously 
described[42] and were plated into tissue culture plates (96 well plates, 15 x 103 cells/well; 12 well 
plates, 150 x 103 cells/well) in standard alpha-MEM supplemented with M-CSF (25 ng/ml) and 
RANKL (100 ng/ml). For studies involving breast cancer cells and their derived factors, M-CSF-
dependent osteoclast precursors were plated into 96 well plates (15 x 103 cells / well) in alpha-
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MEM supplemented with M-CSF (25 ng/ml) and RANKL (100 ng/ml) for 6 hours prior addition of 
MDA-231-BT1, 4T1-BT1 or MCF7 breast cancer cells (300 cells/well) or their conditioned 
medium (20% v/v) prepared as previously described [42]. Cultures were terminated by fixation in 
4% paraformaldehyde, and stained for Tartrate-Resistant Acid Phosphatase (TRAcP). Resorption 
pits were visualised in osteoclast cultures plated on Corning® Osteo Assay Surface multiple well 
plates (Corning, USA) using an Olympus ScanR microscope and resorbed area was quantified by 
ImageJ.  
2.8. Western Blotting 
Western blot analysis was used to detect protein expression. Prior to stimulation with test agents or 
vehicle, cells were incubated in serum free medium for 60 minutes. Test agents or vehicle were 
added and cells were then gently scraped in standard lysis buffer (0.1% (w/v) SDS, 0.5% (w/v) 
sodium deoxycholate, 1% Triton X-100, 1ȝ0 EDTA, 2% (v/v) protease inhibitor cocktail, 10µM of 
sodium fluoride and 2% (v/v) phosphatase inhibitor cocktail) or cytoplasmic lysis buffer (10 mM 
Tris (pH 7.5), 100 mM NaCl, 0.05% NP-40, 3 mM MgCl2, 1 mM EGTA supplemented with 2% 
(v/v) protease and phosphatase inhibitor cocktail). Protein concentration was determined using BCA 
assay (Pierce, USA). Total protein (50 - 70Pg) was resolved by SDS-PAGE (BioRAD, UK) and 
LPPXQREORWWHG ZLWK DQWLERGLHV DFFRUGLQJ WR PDQXIDFWXUHU¶V LQVWUXFWLRQV 'HWHFWLRQ RI QDWLYH DQG
phosphorylated proteins was performed using rabbit monoclonal antibodies (all at 1:1000 dilution, 
cell Signalling Technology, USA). Immuno-complexes were visualised by an enhanced 
chemiluminescence detection kit (Pierce, USA) using horseradish peroxidase-conjugated secondary 
antibody (Jackson labs, UK), and visualised using chemiluminescence (Amersham, UK) on a 
Syngene GeneGnome imaging system. The intensity of the bands was quantified using GeneSnap 
software (Syngene, UK) and level of actin (Sigma-Aldrich, UK) was used for normalization.  
2.9. Quantitative PCR 
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Gene expression was detected using quantitative PCR (qPCR). Briefly, samples were lysed using 
TRIzol reagent and TXDQWLILHGXVLQJDQDQRGURS 7KHUPR6FLHQWLILF DFFRUGLQJ WRPDQXIDFWXUHU¶V
instructions. Complementary DNA (cDNA) was generated using Invitrogen SuperScript III Reverse 
Transcriptase kit according to PDQXIDFWXUHU¶V LQVWUXFWLRQV 3ULPHUV ZHUH GHVLJQHG XVLQJ WKH
Ensembl genome browser, and Roche website. For amplification of mouse OPG (forward primer: 
¶- ATGAACAAGTGGCTGTGCTG-¶ UHYHUVH SULPHU ¶-CAGTTTCTGGGTCATAATGCAA-
¶mouse RANKL (forward primer: ¶-TGAAGACACACTACCTGACTCCTG-¶UHYHUVHSULPHU
¶-CCACAATGTGTTGCAGTTCC -¶ mouse *$3'+ IRUZDUG SULPHU ¶- 
CCTGAATTTTAAGCTACACACAGC -¶UHYHUVHSULPHU¶- CTGGCACTGCACAAGAAGAT -
¶PRXVH5XQ[ IRUZDUGSULPHU¶-CCACAAGGACAGAGTCAGATTACA-¶UHYHUVHSrimer 
¶- TGGCTCAGATAGGAGGGGTA -¶ PRXVH DONDOLQH SKRVSKDWDVH $/3 $.3 $/3/
IRUZDUG SULPHU ¶-AAGGCTTCTTCTTGCTGGTG-¶ UHYHUVH SULPHU
¶GCCTTACCCTCATGATGTCC -¶ were used. Levels of gene expression were expressed as 
copy number per micro-gram of total RNA and GAPDH was used for cDNA normalization.  
2.10. Transcription factors assays 
Nuclear extracts from cultures of mouse M-CSF dependent osteoclast precursors and osteoblasts 
were prepared using a nuclear extract kit (Active Motif, Rixensart, Belgium) and DNA binding was 
measured using TRANSAM ELISA kit for p65 NFNB and c-Fos (Active Motif, Rixensart, 
%HOJLXPDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV  
2.11. ,PPXQRVWDLQLQJIRU1)ț% 
Mature osteoclasts were generated in M-CSF and RANKL-stimulated mouse bone marrow cultures 
as described above. Cultures were permeabilised in Triton X100 (0.1% v/v), stained with rabbit 
anti-p65 NFNB (1:200, Santa Cruz Biotechnology, Dallas, USA) and Alexafluor488-conjugated 
goat±anti-Rabbit antibody (1:200, Fisher Scientific UK, Loughborough, UK) and counterstained 
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with DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride). Cytoplamic and nuclear staining of 
p65NFNB was visualised using a fluorescence microscope (Zeiss, Cambridge, UK). 
2.12. Statistical analysis  
Comparison between groups was assessed by analysis of variance (ANOVA) followed by Dunnet¶V 
post hoc test (SPSS for Windows, version 11). A p-value value of 0.05 or below was considered 
statistically significant. The half maximal inhibitory concentration (IC50) values were calculated 
using GraphPad Prism 4 for windows (V10, Microsoft, USA).  
3. Results 
3.1. Effects of NFNB inhibition on the growth osteotropic breast cancer cells in vitro 
Previous studies have shown that NFNB inhibition reduced the growth of parental breast cancer cell 
lines [5, 44]. In view of the fact that breast cancer cells in the skeleton (osteotropic) exhibit an 
altered phenotype compared to their parental counterpart, we assessed the cytotoxic effect of the 
1)ț% LQKLELWRU PTN against a panel of osteotropic, triple-negative (human MDA-231-BT1/2 and 
mouse 4T1-BT1/2) and estrogen receptor positive (human MCF7) breast cancer cell lines[38-40]. 
PTN reduced the growth of all cell lines tested in a concentration-dependent manner (Fig. S1). The 
concentration of PTN that half maximally inhibited cell viability (IC50) was significantly lower in 
osteotropic cells when compared to their parental control (Table 1). In contrast, PTN had no 
significant effects on the growth of osteoblasts or bone marrow derived osteoclast precursors at 
concentrations up to 10ȝ07DEOH  
3.2. PTN reduces osteoblast support for osteoclastogenesis 
Cells of the osteoblast lineage contribute to breast cancer-induced osteolysis through secretion of 
various osteoclastic factors including RANKL[3, 4, 45]. In this study, we utilized ex vivo organ and 
in vitro osteoblast culture systems to test the effects of NFNB inhibition on osteoblast support for 
osteoclastogenesis in the presence of breast cancer cells or their derived factors. In cancer cell - 
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calvarial organ co-culture, PTN (1PM) inhibited osteoclast formation (Fig. 1A, left panel and Fig. 
S2A) and osteolysis (Fig. 1A, right panel and Fig. 1B) induced by MDA-231-BT1, 4T1-BT1 and 
MCF7 breast cancer cells. Addition of conditioned medium from these cells to calvarial osteoblast ± 
bone marrow co-cultures enhanced osteoclast formation and these effects were significantly 
inhibited in the presence of PTN (1PM) (Fig. 1C). Representative photomicrographs of osteoclasts 
from the experiment described are shown in Fig. S2B. Pretreatment of calvarial osteoblasts with 
PTN (5PM) prior to the addition of condition medium from the osteotropic MDA-231-BT1 cells 
significantly inhibited RANKL/OPG ratio after 24 hours (Fig. 1D). Collectively, these results 
demonstrate that PTN inhibits osteolysis by disrupting breast cancer ± osteoblast ± osteoclast 
crosstalk in the models described. 
3.3. PTN enhances osteoblast proliferation, differentiation and bone nodule formation  
In view of previous findings that showed that NFNB inhibition in osteoblasts enhances bone 
formation[24], we examined the effects of PTN on osteoblast proliferation, differentiation and bone 
nodule formation in the presence and absence of breast cancer derived factors. Treatment of mouse 
calvarial osteoblasts with PTN (0.01PM) increased alkaline phosphatase activity within 24 hours 
(Fig. 2A, left panel) and enhanced bone nodule bone formation after 21 days (Fig. 2B, left panel) 
(p<0.01). Representative photomicrographs of bone nodule formation from the experiment 
described are shown in Fig. 2C. Exposure of mouse calvarial osteoblasts to conditioned medium 
from human MDA-231-BT1 breast cancer cells inhibited alkaline phosphatase activity after 24 (Fig. 
2A, middle panel) and reduced bone nodule bone formation after 14 days (Fig. 2B, middle panel). 
These effects were completely inhibited by PTN (0.01 ± 0.1PM) (p < 0.01). Interestingly, 
conditioned medium from osteotropic 4T1 enhanced alkaline phosphatase activity (Fig. 2A, right 
panel) in osteoblast cultures. Treatment with PTN (0.01 ± 0.1PM) had no effects on alkaline 
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phosphatase activity (Fig. 2A, right panel) in these cultures, but PTN further enhanced the increase 
in bone nodule formation caused by exposure to conditioned medium from 4T1-BT1 (Fig. 2B, right 
panel). A similar increase in alkaline phosphatase activity (Fig. S3A) and bone nodule formation 
(Fig. S3B) was observed in cultures of the osteoblast-like cells MC3T3 treated with PTN for 7 days. 
In addition, exposure of osteoblasts to PTN (0.1PM) increased the mRNA expression of alkaline 
phosphatase and Runx2 after 24 and 72 hours (Fig. 2D), consistent with enhanced alkaline 
phosphatase activity and osteoblast differentiation.  
3.4. NFNB inhibition by PTN enhances E catenin activation and expression in osteoblasts  
Mechanistic studies in calvarial osteoblasts showed that pretreatment with PTN (5ȝ0IRUKRXU
prior to addition of conditioned medium from human MDA-231-BT1 or mouse 4T1-BT1 prevented 
INB phosphorylation after 15 minutes (Fig. 3A-B), inhibited NFNB DNA binding after 45 minutes 
(Fig. 3C) and reduced E-catenin cytoplasmic sequestration and increased its nuclear translocation 
(Fig. 3D-E) after 3 hours. Exposure of osteoblasts to PTN (1PM) for 24 hours enhanced E-catenin 
protein level and reduced the expression of INB (Fig. 3F). These results suggest that the NFNB 
inhibitor PTN enhances E-catenin activation in osteoblast in the presence of breast cancer derived 
factors.  
3.5. Disruption of the NFNB/E catenin pathway by PTN in osteoclasts reduces breast cancer-
induced osteoclastogenesis  
Next, we tested the effects of PTN on breast cancer-induced osteoclastogenesis in the absence of 
osteoblasts. As shown in Fig. 4 (panels A and B), exposure of mouse M-CSF generated osteoclast 
precursors to the breast cancer cells MDA-231-BT1, MCF7 and 4T1-BT1 or their derived factors 
enhanced RANKL-induced osteoclast formation (p < 0.001), and these effects were inhibited by 
PTN in a concentration dependent manner (IC50; 0.13 ± 0.1 for MDA-231-BT1, 0.53 ± 0.2 for 
4T1-BT1 and 4.17 ± 1.2 for MCF7 cells). Representative photomicrographs of osteoclasts from the 
 13 
experiment described are shown in Fig. S2C. Of note, PTN had no effects on the proliferation of M-
CSF generated osteoclast precursors (Fig. S2D-E). This excludes the possibility that the inhibitory 
effect on osteoclast formation was mediated by a reduction in pre-osteoclast cell number. 
Mechanistic studies in osteoclast precursors showed that exposure to PTN (5ȝ0 IRU  KRXU
inhibited INB phosphorylation (Fig. 4C) and p65NFNB DNA binding (Fig. 4D) induced by RANKL 
(100ng/ml) or conditioned medium. Representative microphotographs of p65NFNB nuclear 
translocation in osteoclasts in the presence and absence of PTN (ȝ0 are shown in Fig. S4. 
Additionally, exposure to RANKL (100ng/ml) reduced E-catenin and INB expression in osteoclast 
precursor-like cells RAW 264.7 after 48 hours (Fig. 4F), and these effects were reversed by 
pretreatment with PTN (1PM) (Fig. 4E-F). Collectively, these results demonstrate that 
pharmacological disruption of NFNB - and its interaction with E-catenin - in osteoclasts by PTN 
inhibits RANKL and breast cancer cell support for osteoclastogenesis. 
3.6. PTN induces osteoclast apoptosis  
Mature osteoclast survival is a major determinant of osteolytic bone loss [46]. With this in mind, we 
examined the effects of PTN on osteoclast survival and apoptosis. We generated mature osteoclasts 
and then exposed these cells to PTN in the presence and absence of M-CSF, RANKL or 
conditioned medium from human MDA-231-BT1 cells. As shown in Fig. 5 (panel A), exposure of 
osteoclasts to conditioned medium from MDA-231-BT1 cells (20% v/v) reduced osteoclast death 
due to withdrawal of M-CSF (25ng/ml) or RANKL (100ng/ml). Treatment with PTN (0.1 - 1PM) 
exacerbated osteoclast inhibition in these cultures after 24 hours of continuous treatment (Fig. 5A). 
PTN also induced caspase-3/7 activation in mature osteoclasts after 6 hours (Fig. 5B) and caused 
osteoclast apoptosis after 24 hours (Fig. 5C), as evident by nuclear condensation and DNA 
fragmentation as assessed by DAPI and TUNEL assays, respectively. Osteoclast apoptosis in these 
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cultures was significantly inhibited in the presence of the Caspase inhibitor zVAD-fmk (Fig. 5D), 
indicative of caspase involvement. We also investigate the effects of PTN on osteoclast activity in 
the presence and absence of conditioned medium (10% v/v) from MDA-231-BT1. The results of 
this experiment showed that exposure of mature osteoclasts to MDA-231-BT1 cells significantly 
increased bone resorption, and this was not affected by PTN treatment (1PM) (Fig. S5). 
3.7. PTN reduces breast cancer related osteolysis 
We tested the effects of PTN on osteolytic bone damage caused by breast cancer cells or their 
derived factors in immuno-competent mice (Fig. 6A). Administration of PTN (3mg/kg/3-weekly) in 
immuno-competent mice 24 hours prior to supra-calvarial injection of conditioned medium from 
human MDA-231-BT1, MCF7 and mouse 4T1-BT1 breast cancer cells increased bone volume (Fig. 
6B). Next, we examined the effects of PTN on skeletal tumour growth and bone loss in the 
syngeneic 4T1 model of osteolysis. PTN (10mg/kg/3-weekly) was administered in mice 1 day prior 
to intra-tibial injection of the osteotropic 4T1-BT1 (4×103) and continued to day 12 (Fig. 6C). All 
mice that were treated with vehicle (0.01% DMSO) developed local osteolysis, characterised by a 
significant loss in trabecular bone volume (% BV/TV), thickness (% Tb.Th) and connectivity (% 
Conn.D) (Fig. 6D). These changes were significantly inhibited by treatment with PTN (10mg/kg/3-
weekly). Detailed microCT analysis of tumor growth in the metaphysis of the proximal tibia 
showed that PTN reduced the size of lytic lesions (Fig. 6E), indicative of reduced tumour area. 
Further histomorphometric analysis of bone revealed that PTN reduced osteoclast number 
(Oc.N/BS, Fig. 6F, left panel), suppressed osteoclast activity (Oc.S/BS, Fig. 6F, right panel) and 
enhanced osteoblast number (Ob.N/BS, Fig. G, left panel), without affecting active osteoblast 
surface (Ob.S/BS, Fig. 6G, middle panel) and width (Ob.W, Fig. 6G, right panel).  
4. Discussion 
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Breast cancer cells frequently metastasize to the skeleton in patients with secondary breast cancer 
[1-3]. Osteoclast and osteoblast activity in the tumour microenvironment plays an essential role in 
the regulation of breast cancer cell behaviour in the skeleton[1-4]. 7KH1)ț%signalling pathway 
regulates osteoclast and osteoblast differentiation in health and disease[16, 34, 47]. Previous studies 
have also implicated NFNB in the initiation and progression of bone metastasis [33, 34], and 
phDUPDFRORJLFDO LQKLELWRUVRI1)ț% UHGXFHGEUHDVW FDQFHU-induced osteolysis [33, 34]. However, 
the bone-DXWRQRPRXV FRQWULEXWLRQ RI 1)ț% WR EUHDVW FDQFHU-induced osteolysis is poorly 
understood. This and the fact that most previous studies that have implicated NFNB in bone 
metastasis were performed in immuno-deficient mice have led us to study the bone cell-autonomous 
FRQWULEXWLRQRI1)țB to breast cancer related bone cell activity and osteolysis in vitro, ex vivo and 
in immuno-competent mice.  
Previous studies showed that NFNB inhibition reduced osteolysis and this effect was attributed ± at 
least in part - to the reduction in number of breast cancer cells metastasizing to bone [33, 34]. Here, 
we provide pharmacological evidence to show that bone cell-specific inhibition of NFNB by PTN 
reduced osteolysis induced by conditioned medium from human and mouse breast cancer cells. 
Data from in vitro bone cell and organ cultures and histomorphometric analysis of bone confirmed 
that this agent inhibited breast cancer- and RANKL-induced osteoclast formation and reduced the 
ability of breast cancer cells to prolong osteoclast survival and to inhibit osteoclast apoptosis. It is 
important to note however that this agent had no direct effect on bone resorption by mature 
osteoclasts at concentrations that do not affect osteoclast survival (Fig. S5A-C). Breast cancer- and 
bone-derived mediators other than RANKL are implicated in the regulation of breast cancer ± bone 
cell interactions [3, 4]. In this study, we show that PTN also inhibited NFNB activation by 
TNFDand 7*)ȕLQcultures of osteoclasts and their precursors that have been primed with MDA-
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231-BT1 conditioned medium (Fig. S6). These findings are entirely consistent with the pro-
apoptotic and anti-resorptive effects of this agent, and of great interest in demonstrating that NFNB 
inhibition suppresses excessive osteoclast formation caused by RANKL, breast cancer cells and 
other osteolytic mediators such as TNFDand 7*)ȕ WKDW DUH RIWHQ SUHVHQW LQ WKH ERQH WXPRXU
microenvironment. 
Osteolysis supports the growth of metastatic breast cancer cells in the skeleton [1-3]. Previous 
studies have shown that breast cancer cells in the skeleton exhibit an altered phenotype compared to 
their parental counterpart [1-4]. Here, we show that osteotropic sub-clones of the human MDA-231 
and mouse 4T1 breast cancer cells were sensitive to treatment with PTN when compared to parental 
cells. Furthermore, PTN inhibited tumour area in mice injected with the osteotropic 4T1-BT cells, 
suggesting an anti-tumour effect. Whilst we cannot exclude the possibility that PTN exerts a direct 
inhibitory effect on tumor growth in vivo, it is likely that the anti-tumour effect observed in our in 
vivo model was mainly due to osteoclast inhibition. Evidence to support this hypothesis comes from 
the anti-osteoclast effects observed in vitro, ex vivo and in vivo, and from in vitro studies that 
showed that the concentrations of PTN that needed to inhibit growth of breast cancer cells were at 
least 10 times higher than those that inhibited osteoclast formation. 
NFNB inhibition is associated with increased osteoblast differentiation and maturation[22]. With 
this in mind, we examined the effects of PTN on osteoblast differentiation and activity in the 
presence and absence of conditioned medium from human and mouse breast cancer cells [21, 22, 
27]. PTN reduced osteoblast inhibition by breast cancer cells, as evidenced by marked increase in 
osteoblast differentiation and bone nodule formation, and also by the fact that PTN enhanced ALP 
expression and activity, increased Runx-2 expression and stimulated ȕ-catenin activation in 
osteoblasts. Moreover, PTN had no effects on osteoblast apoptosis in the presence or absence of 
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conditioned medium from breast cancer cells (data not shown). It is important to note however that 
administration of PTN in mice stimulated osteoblast number but had no significant effects on bone 
formation rate in the 4T1 model described. Future in vivo studies in models of osteolysis are needed 
to evaluate the consequences and implications of osteoblast stimulation by PTN in the treatment of 
breast cancer bone metastasis. 
NFNB cooperates with multiple signaling pathways in bone and breast cancer cells [32]. One of the 
transcription factors that is essential for osteoclast formation is c-Fos [48]. In this study, we showed 
that exposure of osteoclasts and their precursors to PTN reduced the phosphorylation and DNA 
binding of c-Fos by TNFD-, RANKL- or MDA-231-BT1 conditioned medium (Fig. S7). Previous 
studies KDYH LPSOLFDWHG ȕ-catenin in the stabilization and cytoplasmic sequestration of 
p65NFNB[32]. :QWȕ-catenin signalling plays a role in the regulation of osteoclast and osteoblast 
GLIIHUHQWLDWLRQ DQG 6FOHURVWLQ D VHFUHWHG LQKLELWRU RI :QWȕ-catenin signalling reduces bone 
formation[25-27, 32]. In broad agreement with these findings, we showed that NFNB inhibition by 
PTN in osteoblasts and osteoclasts was accompanied by a significant increase in ȕ-catenin 
activation and expression. Notwithstanding this, we cannot exclude the involvement of other 
mechanisms since PTN has been reported to affect a wide array of cellular processes including 
DNA methylation and generation of reactive oxygen species[37]. 
In conclusion, our present data together with previous results obtained from immuno-deficient mice 
[33, 34] suggest that NFNB plays a key role in the regulation of breast cancer-induced bone cell 
activity and osteolysis. We also presented pharmacological evidence to suggest that bone-specific 
inhibition of NFNB suppresses osteoclast formation and reduces osteoblast inhibition related to 
breast cancer by engaging E-catenin signalling. When combined with previous studies[32], our 
 18 
present results raise WKHSRVVLELOLW\WKDWFRPELQHGWDUJHWLQJRI1)ț%DQGȕ-catenin signalling may 
be of value in the treatment of breast cancer associated bone disease.  
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Figure legends: 
 
Fig. 1. PTN reduces osteoblast support for osteoclastogenesis. (A) Ex vivo osteoclast number and 
bone resorption in mouse calvarial organ culture exposed to conditioned medium (20% v/v) from 
human MDA-231-BT1 and MCF7 or mouse 4T1-BT1 cancer cells in the presence and absence of 
PTN (1PM). (B) Representative photomicrographs of osteolytic bone damage from the experiment 
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described in panel A. (C) In vitro osteoclast formation in mouse calvarial osteoblast - bone marrow 
cell co-cultures after exposure to conditioned medium (CM, 20% v/v) from human MDA-231-BT1 
and MCF7 or mouse 4T1-BT1 cancer cells in the presence and absence of PTN (1PM). (D) mRNA 
expression of RANKL and OPG in mouse calvarial osteoblasts exposed to conditioned medium 
(20% v/v) from human MDA-231-BT1 breast cancer cells in the presence and absence of PTN 
ȝ0. Values are mean ± SD; * p<0.05 and ** p<0.01 from vehicle; + p<0.05 from vehicle plus 
breast cancer cells or conditioned medium. 
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Fig. 2. PTN enhances osteoblast differentiation and protects against osteoblast inhibition by 
breast cancer cells. (A-B) In vitro osteoblast differentiation (A) and bone nodule formation (B) in 
mouse calvarial osteoblast cultures exposed to standard or conditioned medium (20%v/v) from 
human MDA-231-BT1 or mouse 4T1-BT1 cancer cells in the presence or absence of PTN for 24 
hours. (C) In vitro bone nodule formation in mouse calvarial osteoblasts (21 days) and Saos2 (10 
days) treated with PTN at the indicated concentration in the presence and absence of conditioned 
medium from MDA-231-BT1 and 4T1-BT1. Osteoblast differentiation and bone nodule formation 
were assessed by Alkaline phosphatase (ALP) and Alazarin Red assays. (C) Representative 
photomicrographs of osteoblasts and bone nodule formation from the experiment described in panel 
B. (D) mRNA expression of ALP and Runx2 in mouse calvarial osteoblasts after 24 and 72 hours in 
the presence or absence of PTN (0.ȝ0. Values are mean ± SD; * p<0.05 and + p<0.05 from 
vehicle plus breast cancer cell conditioned medium. 
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Fig. 3. PTN activates ȕ-catenin signalling in osteoblasts. (A-B) Western blot analysis (A) and 
quantification (B) of total and phosphorylated INB in mouse calvarial osteoblast cultures pretreated 
ZLWKYHKLFOHRU371ȝ0IRUKRXUDQGexposed to conditioned medium 20%v/v) from human 
MDA-231-BT1 or mouse 4T1-BT1 cancer cells for 15 minutes. (C1)ț%'1$ELQGLQJLQPRXVH
calvarial osteoblasts cultures preWUHDWHG ZLWK YHKLFOH RU 371 ȝ0 IRU  KRXU DQG exposed to 
conditioned medium (20% v/v) from human MDA-231-BT1 (left) or mouse 4T1-BT1 (right) cancer 
cells for 45 minutes. (D-E) Western blot analysis (D) and quantification (E) of E-catenin expression 
in cytoplasm (Cyt) and nuclear (Nuc) fractions obtained from mouse calvarial osteoblasts cultures 
preWUHDWHGZLWKYHKLFOHRU371ȝ0IRUKRXUDQGexposed to standard medium or conditioned 
medium (20%v/v) from human MDA-231-BT1 breast cancer cells for 3 hours. (F) Differential 
expression of E-Catenin and Iț%REWDLQHGIURPPRXVHFDOYDULDORVWHREODVWFXOWXUHGLQWKHSUHVHQFH
or absence of PTN at the indicated concentration for 24 hours. Values are mean ± SD; * p<0.05 and 
** p<0.01 from vehicle; + p<0.05 from vehicle plus breast cancer cell conditioned medium. 
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Fig. 4. PTN inhibits breast cancer cell- and RANKL-induced osteoclast formation. (A-B) In 
vitro osteoclastogenesis of murine M-CSF (25ng/ml) and RANKL (100ng/ml) stimulated bone 
marrow treated ZLWKYHKLFOHRU371ȝ0in the presence and absence of breast cancer cells (A) or 
their conditioned medium (20%v/v) (B) for 48 hours. (C) Western blot analysis of total and 
phosphorylated INB in cultures of M-CSF (25ng/ml) dependent pre-osteoclasts after exposure to 
human RANKL (100ng/ml), human M-CSF (25ng/ml) or conditioned medium (20% v/v) from 
human MDA-231-BT1, 4T1-BT1 and MCF7 cancer cells in the presence and absence of PTN 
ȝ0 D 1)ț% '1$ ELQGLQJ in cultures of M-CSF (25ng/ml) dependent pre-osteoclasts 
described in panel C. (E-F) Differential expression of E-Catenin and Iț% LQ PRXVH 5$: 
macrophage (pre-osteoclasts) pretreated with vehicle or PTN (1ȝ0IRUKRXUDQGcultured in the 
presence or absence of RANKL (100ng/ml) for 48 hours. Values are mean ± SD; * p<0.05 and ** 
p<0.01 from vehicle; + p < 0.05 from vehicle plus breast cancer cells or conditioned medium; $ 
p<0.05 from vehicle and RANKL treated cultures. 
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Fig. 5. PTN induces osteoclast apoptosis. (A) In vitro survival of mature osteoclasts after 
withdrawal of human RANKL (100ng/ml), M-CSF (25ng/ml), or both followed by exposure to 
MDA-231-BT1 conditioned medium (20%v/v) in the presence or absence of PTN for 24 hours. (B-
C) In vitro caspase-3/7 activation (B) DNA fragmentation (C) in mature osteoclasts from the 
experiment described in panel A after 6 and 24 hours, respectively. (D) In vitro osteoclast apoptosis 
in cultures treated with PTN (10PM) in the presence of absence of the caspase inhibitor zVAD-fmk 
(20ȝ0 Values are mean ± SD; * p<0.05 and ** p<0.01 from vehicle; $ p<0.05 from vehicle plus 
breast cancer conditioned medium; + p < 0.05 from PTN plus caspase inhibitor zVAD-fmk. 
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Fig. 6. PTN inhibits skeletal tumour growth and reduces breast cancer-induced osteolysis. (A) 
Graphic representation of supracalvarial injection of conditioned medium (CM) from human MDA-
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231-BT1 and MCF7 and mouse 4T1-BT1 breast cancer cells in immunocompetent mice pretreated 
with vehicle or PTN (3mg/kg/day) for 3 days. (B) Total bone volume from the experiment 
described in panel A (n = 7). (C) Graphic representation of intra-tibial injection of the mouse breast 
cancer osteotropic 4T1-BT1 in immunocompetent BALB/c mice pretreated with vehicle 
(DMSO/water: 0.1:10) or PTN (10mg/kg/day) for 12 days. (D) Total bone volume (BV/TV), 
trabecular thickness (Tb.Th.) and connectedness density (Conn.D) in tibial metaphysis of mice from 
the experiment described in panel C. (E) Tumour size from the experiment described in panels C-D. 
(F) In vivo osteoclast formation (Oc.N, left panel) and activity (Oc.S/BS, right panel) from the 
experiment described in panels C-D. (G) In vivo osteoblast number (Ob.N, left panel), osteoid 
surface (Ob.S/BS, middle panel) and osteoid width (Ob.W, right panel) from the experiment 
described in panels C-F. Values are mean ± SD; * p<0.05 and ** p<0.01 from vehicle plus breast 
cancer cells or conditioned medium. 
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Tables: 
Table I 
Effects of Parthenolide on the growth of osteotropic breast cancer cells in vitro. 
 
 
 
Cell viability (IC50, PM) 
 
  
MDA-231 10.57 ± 0.15 
 
MDA-231-BT1 8.17 ± 0.62 
 
MDA-231-BT2 7.82 ± 0.69 
 
MCF7 12.7 ± 1.10 
 
4T1 6.79 ± 0.18 
 
4T1-BT1 5.72 ± 0.61 
 
4T1-BT2 1.90 ± 0.56 
 
Pre-Osteoclasts > 10 
 
Osteoblasts > 10 
 
 
 
Cell viability was measured after 48 hours of continuous exposure to PTN by AlamarBlue assay. Calculation 
RI KDOI PD[LPDO LQKLELWRU\ FRQFHQWUDWLRQV ,& KDV EHHQ SHUIRUPHG DV GHVFULEHG XQGHU ³0DWHULDOV DQG
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0HWKRGV´9DOXHVDUHPHDQ6'DQGDUHREWDLQHGIURPLQGHSHQGHQWH[SHULPHQWV%7denotes osteotropic 
tropic cells, and pre-osteoclasts refers to M-CSF generated osteoclast precursor cells.  
 
 
 
 
 
 
 
